Personalising the use of chemotherapy in breast cancer treatment

(Medical Xpress) -- UCD researchers have identified a novel biomarker that can identify those women with breast cancer who will have a poor response to tamoxifen, one of the principle anti-hormone drugs used to treat the disease. This may allow clinicians to tailor the treatment of early stage breast cancer patients appropriately.

Read the whole article on Physorg

More from Physorg